Table 3 Anticancer drugs most often prescribed to patients in the study

From: Cancer and renal insufficiency results of the BIRMA study

INN

No. of prescriptions

Percent of prescription (%)

Need for dosage adjustment in RI

Potential nephrotoxicity

Fluorouracil

248

13.6

No

No

Zoledronate

220

12.1

Yes

Yes

Docetaxel

114

6.2

Yes

No

Cyclophosphamide

101

5.5

Yes

No

Epirubicin

94

5.2

No

SC

Trastuzumab

92

5.0

ND

SC

Gemcitabine

90

4.9

No

Yes

Cisplatin

89

4.9

Yes

Yes

Carboplatin

70

3.8

Yes

Yes

Paclitaxel

63

3.5

No

SC

Oxaliplatin

61

3.3

No

Yes

Irinotecan

53

2.9

No

Yes

Doxorubicin

52

2.8

No

SC

Capecitabin

47

2.6

Yes

No

Letrozole

42

2.3

No

No

Tamoxifen

41

2.2

No

SC

Ibandronate

35

1.9

Yes

No

Vinorelbine

32

1.8

Yes

No

Exemestane

30

1.6

No

No

Temozolomide

22

1.2

ND

No

Cetuximab

18

1.0

No

Yes

Other

238

12.9

Yes: 28.2%

Yes: 100 prescriptions

   

ND: 31.5%

ND: 18 prescriptions

   

No: 40.3%

No: 100 prescriptions

Total

1852

100

Yes: 41.8%

Yes: 1043 prescriptions

   

ND: 10.2%

ND: 18 prescriptions

   

No: 47.9%

No: 791 prescriptions

  1. Abbreviations: INN=international non-proprietary name; ND=no data available in the literature for use in patient with RI or for nephrotoxicity; RI=renal insufficiency; SC=sparse cases.
  2. Other: anticancer drugs that were prescribed in <1% of patients in the study (decreasing number of prescriptions): bevacizumab, gosereline, etoposide, fulvestrant, methotrexate, topotecan, anastrozole, dacarbazine, vinblastine, erlotinib, vinflunine, mitoxantrone, bicalutamide, mitomycine, megestrole, pamidronate, imatinib, ifosfamide, vaccine, bleomycin, lomustin, estramustin, fotemustin, gefitinib, leuproreline, octreotide, hydroxycarbamide, pemetrexed, triptoreline, sunitinib, panitumumab, thyrixine, cyproterone, carmustine, rituximab, streptozocine, matuzumab, sorafenib, lanreotide, ipilimumab.
Back to article page